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Abstract 
Spontaneous ruptures of hepatocellular carcinoma (HCC) are rare. Nevertheless they may 
lead to difficult decisions in the emergency situation. The acute therapies include conserva-
tive treatment, transarterial embolization and surgery. Curative treatment of HCC can be 
achieved by liver resection solely. The decision-making depends on prognostic patient’s fac-
tors, such as hepatic viral infection status, Child-Pugh grade, liver cirrhosis and number of 
tumors. In this case transarterial embolization was preferable as a bridging therapy prior to 
further diagnostics and therapy, to lower the perioperative morbidity and mortality. The 
therapy of these cases needs an interdisciplinary approach to choose the best possible pro-
cedure in each case. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Hepatocellular carcinoma (HCC) has worldwide an incidence of approximately 15 per 
100,000. Especially in developing regions, HCC is a major problem. Subsequently it has an 
incidence of up to 32 per 100,000 in eastern Asia, whereas it reaches an incidence of 5 per 
100,000 in northern Europe. Women are less often affected than men [1]. Patients with liver 
cirrhosis due to any etiology and patients with non-cirrhotic liver, but with chronic hepatitis 
or non-alcoholic steatohepatitis are at risk for cancer development as well [2]. The incidence 
of HCC will increase in the next few years due to the increased incidence of liver cirrhosis in 
chronic hepatitis B and C and alcoholic and non-alcoholic liver disease [3]. The staging of the 
tumor follows the international guidelines of the WHO and the TNM classification [4]. 
Rupture of the tumor with subsequent intraperitoneal hemorrhage is a life-threatening 
condition. In patients diagnosed with HCC, rupture occurs in 3–15%, with a high in-hospital 
mortality rate of 25–75% [3]. Especially in patients without a previous history of liver cir-
rhosis or HCC, diagnosing a ruptured tumor may be difficult, because of the missing patient 
history and the rare disease. 
Here we report the case of an elderly patient with spontaneous ruptured advanced-
staged HCC, which was detected for the first time in the emergency room and required a 
special approach. 
Case Presentation 
A 79-year-old man presented with an episode of upper gastrointestinal bleeding. A gas-
troscopy and a colonoscopy were performed, where an active bleeding was absent. There-
fore, a duodenal polyp was suspected as the possible site of bleeding. Because of the platelet 
inhibition with aspirin, the polyp was not excised in this endoscopic session. 
One week later, the patient presented again to the emergency department and com-
plained of sudden abdominal pain in the upper quadrants. At the time of admission, the pa-
tient was cardiopulmonarily stable. In the clinical examination, there was a distinct tender-
ness on abdominal palpation in the upper right quadrant. In an interval of 4 h, hemoglobin 
level decreased from 11.4 to 9.1 g/dL. There was no sign for coagulopathy (INR 1.1) and the 
liver enzymes (ALAT 16 U/L, ASAT 26 U/L, ALP 62 U/L, bilirubin 3 μmol/L) were normal. 
The performed X-ray of the abdomen excluded any free intraperitoneal air. In the presence 
of morphin-resistent pain, a contrast-enhanced computed tomography (CT) scan of the ab-
domen was performed. It showed a perforated tumor in segment IVb of the liver. The perfo-
rated tumor was actively bleeding into the peritoneal and mesenteric space (Fig. 1). 
An emergent interdisciplinary discussion was initiated. To achieve hemostasis, we initi-
ated a transarterial embolization (TAE). By a superselective angiography of the liver arteries 
with embolization of the segmental arteries IV and V with Embosphere particles (100–300 
μm), an adequate hemostasis was achieved. Although the tumor was highly vascularized, no 
active bleeding was seen during this intervention. The control showed a successful emboli-
zation (Fig. 2). 
After clinical recovery of the patient, further radiological examinations were made. One 
month after diagnosis, the liver magnetic resonance imaging (MRI) showed a cirrhotic liver 
with a tumor of 85 × 72 × 75 mm in segment IV with a necrotic cavity, but no signs of further 
bleeding or ascites (Fig. 3). Six additional T2-hyperintense lesions with a maximum diameter 
of 11 mm were detected in segments II, III, and IVa/b. Metastatic disease was excluded by 
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thoracic and abdominal CT scan. Because of the tumor perforation and tumor size, an ad-
vanced-stage HCC according to the Milan criteria was diagnosed [5]. The tumor markers 
alpha-fetoprotein (4 U/mL), CA 19-9 (15 U/L), and CEA (2.4 ng/mL) were in the normal 
reference range. The serological findings were negative for hepatitis (HBVs antigen, HBV 
antibody, HCV antibody). Cirrhotic liver was classified as Child-Pugh A. 
In the absence of a systemic progress, we decided for a selective transarterial radioem-
bolization (TARE). During TARE planning, the gastroduodenal artery was coiled. In a second 
outpatient procedure, the whole liver was treated with a total of 6.2 GBq (3.7 GBq into the 
right liver lobe, 2.5 GBq into the left liver lobe) in a split-dose fashion using yttrium-90 glass 
spheres (Therasphere, BTG). 
One month later, the patient presented with a minimal tumor growth. Because of the 
slight progress, a follow-up after 2 months was initiated. This follow-up showed a significant 
regression of the primary tumor and the satellite lesions as well. Solely one new lesion in 
segment VII could be identified. Progressive disease with a growing primary tumor, satellite 
lesions, and an increase of alpha-fetoprotein (47 U/mL) was diagnosed 6 months after TARE 
(Fig. 3). Metastatic disease was excluded again. As a result, palliative treatment was imple-
mented. A transarterial chemoembolization (TACE) of the left hepatic artery with doxorubi-
cin 100 mg was performed 1 month later. A planed MRI and chemoembolization of the right 
hepatic lobe were omitted due to the rapid deterioration of the patient’s general health. 
Barely 2 weeks after TACE, the patient developed a septic cholangitis caused by an Entero-
coccus coli superinfection of the necrotic tumor. Despite an antibiotic therapy with piperacil-
lin-tazobactam, the patient developed a multi-organ dysfunction. Therefore, we implement-
ed a palliative therapy and the patient died 3 weeks after diagnosis of the cholangitis and 
almost 1 year after onset of symptoms. 
Discussion 
In this case report, we present a challenging patient who presented with an acute ab-
domen without a prior history of liver disease and was diagnosed with a ruptured HCC. This 
urgent diagnosis requires the emergency discussion with an interdisciplinary team to opti-
mize the treatment. 
In a situation of acute abdomen and a diagnosed HCC, the possible rupture of HCC must 
be included in the differential diagnosis. The abrupt onset of abdominal pain is the most 
common symptom in 66–100%, followed by shock in 33–90% of the patients [6]. Diagnosis 
should be made by sonography or CT, which can demonstrate the tumor and the hematoper-
itoneum. We use CT as standard examination because it can define the hypervascularization 
of tumors, the anatomy of hepatic arteries, the periportal lymph nodes, and the patency of 
the portal vein as well. Moreover, it is quickly available in the emergency setting. 
For the new diagnosis of a ruptured HCC, an adequate workup is often missing in the 
emergency room. Additionally, hemorrhagic shock decreases liver function. The acute thera-
pies include conservative treatment, TAE, and surgery. The decision-making depends on 
prognostic patient’s factors, such as hepatic viral infection status, Child-Pugh grade, liver 
cirrhosis, and number of tumors. The management of a ruptured HCC in the acute phase 
aims to achieve hemostasis and preservation of functional liver parenchyma. Treatment 
options should be discussed on an interdisciplinary panel and is based on multiple factors 
(Fig. 4). Single-stage emergency liver resection has an in-hospital mortality of 16–100% [3]. 
TAE is a good option to reach hemostasis in the acute situation of a ruptured HCC. The only 
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contraindication for TAE is a complete occlusion of the main portal vein by the tumor, which 
may cause hepatic infarction. Occluding the afferent vessels distally by TAE may achieve 
better hemostasis than surgery with a high success rate of 53–100% [3]. In this case, a first-
line surgical procedure was not feasible because of the unknown stage of the tumor, the 
missing etiology, and the disadvantages of an emergency resection. We decided to perform 
TAE of the tumor as a bridging therapy for further diagnostics and a significant improve-
ment of overall survival [7]. 
The AJCC/UICC (American Joint Committee on Cancer/Union for International Cancer 
Control) classifies all ruptured HCCs as stage T4 in current TNM staging [8]. But outcomes 
may be better comparable in the pre-ruptured stage, e.g., ruptured T2 HCC have a signifi-
cantly better overall survival than ruptured T3 and T4 HCC [7]. Liver resection is the only 
curative approach for patients with ruptured or non-ruptured HCC. To decide whether a 
tumor is resectable or not, a complete staging is essential. As a decision guideline, the Barce-
lona Clinic Liver Cancer classification (BCLC) may be used, which integrates tumor stage, 
liver function, and general conditions of the patient as well [9]. Generally, solely patients 
with Child A/B cirrhotic liver and without or with mild portal hypertension should have 
surgical resection. Otherwise, non-resectability is due to extrahepatic tumor, poor patient’s 
condition and comorbidity, tumor infiltration into all liver veins, or lack of functional liver 
after resection [2]. In contrast to emergency procedure, staged liver resection has a much 
lower in-hospital mortality rate of 0–9% [3]. Consequently, emergency liver resection should 
be reserved for patients with diagnosed HCC in which an R0 resection is possible and with 
sufficient liver function. In cases with insufficient functional liver, e.g., due to liver cirrhosis, 
transplantation may be evaluated. All Milan criteria must be fulfilled. Additionally, the tumor 
must be diagnosed by biopsy and either by an elevated alpha-fetoprotein level (>400 U/mL) 
and a hypervascularized tumor in radiology or by a hypervascularized tumor in two radio-
logic methods [10]. 
This patient did not qualify for surgical resection due to his advanced tumor stage. We 
decided for a bridging therapy to slow tumor progression. Normally, a duplication of tumor 
size is achieved in approximate 4 months [11]. The bridging therapy was started after reach-
ing hemostasis and recovery of the patient. Radiofrequency ablation, TARE, TACE, or system-
ic chemotherapeutic sorafenib are such bridging procedures. These may bridge time to-
wards transplantation, stop potential tumor growth, or even downstage a tumor. After in-
terdisciplinary discussion, we decided to perform TARE. This decision was made because of 
the advanced tumor stage in combination with the missing systemic progression. 
Decision-making in these complex patients has to be interdisciplinary, as many parame-
ters change during the course of illness and non-operative options may be better suited to 
improve quality of life and survival. 
Conclusion 
TAE was able to stop the bleeding. Because of interval tumor progression, further 
transarterial therapies were applied (TARE and TACE). However, after 1 year after onset of 
symptoms, the patient died. During treatment of patients with ruptured HCC, it is of high 
importance that all involved physicians act as an interdisciplinary team. There are many 
factors in the decision-making process, which needed to be evaluated by specialists. The 
treatment of ruptured HCC needs to be a consensus of emergency doctors, gastroenterolo-
gists, interventional radiologists, and surgeons as well. 
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Fig. 1. Computed tomography of the abdomen. The axial plane (a) as well as the coronal plane (b) in the 
computed tomography scan of the abdomen showed a hepatic tumor (asterisk) with 6 cm diameter and 
perihepatic fluid. 
 
 
 
Fig. 2. Transarterial embolization. After puncture of the right femoral artery, a catheter was advanced via 
the celiac trunc into the common hepatic artery, and the segmental arteries IV and V were selectively em-
bolized with particles (Embosphere 100–300 μm). A highly vascularized tumor without active bleeding is 
shown in angiography before embolization (a) in segment IV. After tumor embolization, the former hyper-
vascularity of the tumor is absent (b). 
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Fig. 3. Residual tumor in magnetic resonance imaging (T2) 1 month after embolization and progression 
especially in other parts of the liver in computed tomography of the abdomen 7 months after embolization. 
The axial plane (a) as well as the coronal plane (b) in the T2-weighted magnetic resonance imaging showed 
a residual tumor in segment IV (arrow) and several new tumors, here one shown in segment III (asterisk). 
After 7 months, multifocal appearance of the HCC on computed tomography with primary tumor (arrow) 
and smaller tumors (asterisk) in both lobes was seen on the axial plane (c) as well as the coronal plane (d). 
 
 
 
Fig. 4. Flowchart of emergency and definitive treatment of ruptured hepatocellular carcinoma. HCC, hepa-
tocellular carcinoma; TAE, transarterial embolization. 
 
